<DOC>
	<DOC>NCT01112865</DOC>
	<brief_summary>Convenience and preference for the new Mark VII pen compared to the current Genotropin pen will be assessed using a questionaire. it is expected that the new pen will be preferred or at least no different to the current pen.</brief_summary>
	<brief_title>Cross Over Convenience And Preference Study Of New Mark VII Compared To Genotropin Pen In Pediatric And Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<criteria>Age greater than or equal to 8 years. Subjects who are starting treatment with growth hormone (Genotropin) for the first time. Subjects with PraderWilli syndrome or chronic renal insufficiency. Subjects and caregivers who, in the opinion of the investigator are not able to adequately participate in the study. Subjects with chronic systemic disorders, such as diabetes and heart disease.</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Growth Hormone Deficiency</keyword>
	<keyword>Somatropin</keyword>
	<keyword>Injection Pen</keyword>
	<keyword>Medical Device</keyword>
	<keyword>Cross Over Study</keyword>
	<keyword>Preference</keyword>
	<keyword>Convenience</keyword>
	<keyword>Children</keyword>
	<keyword>Dyads</keyword>
	<keyword>Adults</keyword>
</DOC>